This is good news, but I sure would like to see more updates about the work being done with autologous stem cell transplants for Parkinson's. Autologous cells are derived from the patient, so there are no immune issues as the body recognizes the transplanted cells as "self" (and no need for immunotherapy/
immunosuppression). There is also evidence that autologous cells form synapses with neighboring cells better than allogenic cells (not derived from the patient). Both of those become bigger issues if a patient will need not one, but two, three, or more transplants during his/her lifetime.

Jeanne Loring's department is working on this at Scripps, here's a partial description of the work: (link here:
The Loring Lab)

"Stem cell projects:

Human disease: We have basic and translational projects studying several human diseases, using technologies that range from making disease-specific induced pluripotent stem cells (iPSCs) from patient skin biopsies to experimental transplantation strategies. Our most advanced translational project is development of a stem cell therapy for Parkinson's disease. We are also researching stem cell-based therapies for multiple sclerosis and autism."

Loring stepped down last summer from her role as chief science officer of Aspen Neuroscience, which she helped co-found. Aspen Neuroscience has a couple of candidates they are working on:

An Autologous Stem Cell-Based Therapy for Parkinson's Disease

One good thing about these two research teams is that they recognize there are different types of PD and are developing therapies accordingly.

These therapies will not come in time for so many suffering with Parkinson's, but at least I have hope that family members of those patients may one day be spared the same journey.

In the meantime, dance, box, and keep moving